Evogene Company Profile (NYSE:EVGN)

About Evogene

Evogene logoEvogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: EVGN
  • CUSIP:
Key Metrics:
  • Previous Close: $6.40
  • 50 Day Moving Average: $6.68
  • 200 Day Moving Average: $6.77
  • 52-Week Range: $5.93 - $9.32
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.00
  • P/E Growth: 0.00
  • Market Cap: $162.86M
  • Outstanding Shares: 25,447,000
  • Beta: 0.68
Profitability:
  • Net Margins: -173.92%
  • Return on Equity: -16.25%
  • Return on Assets: -15.04%
Debt:
  • Current Ratio: 18.12%
  • Quick Ratio: 18.12%
Additional Links:
Companies Related to Evogene:

Analyst Ratings

Consensus Ratings for Evogene (NYSE:EVGN) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $9.00 (40.63% upside)

Analysts' Ratings History for Evogene (NYSE:EVGN)
Show:
DateFirmActionRatingPrice TargetDetails
8/17/2016Credit Suisse Group AGLower Price TargetOutperform$19.00 -> $10.00View Rating Details
11/19/2015Piper Jaffray Cos.Lower Price TargetNeutral$12.00 -> $8.00View Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Evogene (NYSE:EVGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/11/2016Q2($0.11)($0.18)$5.36 million$3.82 millionViewListenView Earnings Details
5/19/2016Q1($0.11)($0.13)$2.70 million$2.00 millionViewListenView Earnings Details
3/1/2016Q415($0.17)($0.22)$3.90 million$2.46 millionViewN/AView Earnings Details
11/18/2015Q315($0.15)($0.13)$3.50 million$3.31 millionViewListenView Earnings Details
8/5/2015Q215($0.19)($0.20)$4.40 million$2.66 millionViewN/AView Earnings Details
5/19/2015Q115($0.20)($0.13)$3.65 million$2.70 millionViewListenView Earnings Details
2/26/2015Q4($0.12)($0.19)ViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.17)$4.20 million$3.16 millionViewN/AView Earnings Details
8/20/2014Q214($0.11)($0.22)$7.71 millionViewN/AView Earnings Details
5/8/2014Q1 14($0.12)($0.09)ViewN/AView Earnings Details
3/19/2014Q413($0.08)($0.20)$4.95 million$4.41 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Evogene (NYSE:EVGN)
Current Year EPS Consensus Estimate: $-0.43 EPS
Next Year EPS Consensus Estimate: $-0.32 EPS

Dividends

Dividend History for Evogene (NYSE:EVGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Evogene (NYSE:EVGN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Evogene (NYSE:EVGN)
DateHeadline
publicnow.com logoEvogene Announces Joint Microbial Diversity Activity with University of Missouri (NYSE:EVGN)
www.publicnow.com - September 13 at 9:47 AM
finance.yahoo.com logoEvogene Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016 (NYSE:EVGN)
finance.yahoo.com - September 1 at 4:50 PM
capitalcube.com logoETF’s with exposure to Evogene Ltd. : August 25, 2016 (NYSE:EVGN)
www.capitalcube.com - August 25 at 4:58 PM
streetinsider.com logoCredit Suisse Cuts Price Target on Evogene (EVGN) to $10 Following 2Q (NYSE:EVGN)
www.streetinsider.com - August 17 at 10:11 PM
capitalcube.com logoEvogene Ltd. :EVGN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NYSE:EVGN)
www.capitalcube.com - August 15 at 5:02 PM
sg.finance.yahoo.com logoEvogene reports 2Q loss (NYSE:EVGN)
sg.finance.yahoo.com - August 11 at 5:03 PM
publicnow.com logoEvogene Reports Second Quarter 2016 Financial Results (NYSE:EVGN)
www.publicnow.com - August 11 at 5:03 PM
publicnow.com logoEvogene Appoints a New Member to Board of Directors and a New Chief Operating Officer (NYSE:EVGN)
www.publicnow.com - August 11 at 5:03 PM
publicnow.com logoEvogene to Participate at Piper Jaffray Global Agriculture Symposium (NYSE:EVGN)
www.publicnow.com - August 1 at 8:11 AM
publicnow.com logoEvogene Second Quarter 2016 Earnings Announcement Schedule (NYSE:EVGN)
www.publicnow.com - July 25 at 8:08 AM
finance.yahoo.com logoEvogene to Present at Crops and Chemicals 2016 Conference (NYSE:EVGN)
finance.yahoo.com - July 13 at 7:00 AM

Social

Evogene (NYSE:EVGN) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff